Literature DB >> 16183392

Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administration.

Michael F Hughes1, Vicenta Devesa, Blakely M Adair, Miroslav Styblo, Elaina M Kenyon, David J Thomas.   

Abstract

Exposure to monomethylarsonic acid (MMA(V)) and monomethylarsonous acid (MMA(III)) can result from their formation as metabolites of inorganic arsenic and by the use of the sodium salts of MMA(V) as herbicides. This study compared the disposition of MMA(V) and MMA(III) in adult female B6C3F1 mice. Mice were gavaged p.o. with MMA(V), either unlabeled or labeled with 14C at two dose levels (0.4 or 40 mg As/kg). Other mice were dosed p.o. with unlabeled MMA(III) at one dose level (0.4 mg As/kg). Mice were housed in metabolism cages for collection of excreta and sacrificed serially over 24 h for collection of tissues. MMA(V)-derived radioactivity was rapidly absorbed, distributed and excreted. By 8 h post-exposure, 80% of both doses of MMA(V) were eliminated in urine and feces. Absorption of MMA(V) was dose dependent; that is, there was less than a 100-fold difference between the two dose levels in the area under the curves for the concentration-time profiles of arsenic in blood and major organs. In addition, urinary excretion of MMA(V)-derived radioactivity in the low dose group was significantly greater (P < 0.05) than in the high dose group. Conversely, fecal excretion of MMA(V)-derived radioactivity was significantly greater (P < 0.05) in the high dose group than in the low dose group. Speciation of arsenic by hydride generation-atomic absorption spectrometry in urine and tissues of mice administered MMA(V) or MMA(III) found that methylation of MMA(V) was limited while the methylation of MMA(III) was extensive. Less than 10% of the dose excreted in urine of MMA(V)-treated mice was in the form of methylated products, whereas it was greater than 90% for MMA(III)-treated mice. In MMA(V)-treated mice, 25% or less of the tissue arsenic was in the form of dimethylarsenic, whereas in MMA(III)-treated mice, 75% or more of the tissue arsenic was in the form of dimethylarsenic. Based on urinary analysis, administered dose of MMA(V) did not affect the level of its metabolites excreted. In the tested range, dose affects the absorption, distribution and route of excretion of MMA(V) but not its metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183392      PMCID: PMC2366034          DOI: 10.1016/j.taap.2005.02.008

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  42 in total

1.  The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic.

Authors:  S V Kala; M W Neely; G Kala; C I Prater; D W Atwood; J S Rice; M W Lieberman
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

2.  Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India.

Authors:  B K Mandal; Y Ogra; K T Suzuki
Journal:  Chem Res Toxicol       Date:  2001-04       Impact factor: 3.739

3.  Methylated trivalent arsenic species are genotoxic.

Authors:  M J Mass; A Tennant; B C Roop; W R Cullen; M Styblo; D J Thomas; A D Kligerman
Journal:  Chem Res Toxicol       Date:  2001-04       Impact factor: 3.739

4.  Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic.

Authors:  H V Aposhian; E S Gurzau; X C Le; A Gurzau; S M Healy; X Lu; M Ma; L Yip; R A Zakharyan; R M Maiorino; R C Dart; M G Tircus; D Gonzalez-Ramirez; D L Morgan; D Avram; M M Aposhian
Journal:  Chem Res Toxicol       Date:  2000-08       Impact factor: 3.739

5.  Identification, characterization, and crystal structure of the Omega class glutathione transferases.

Authors:  P G Board; M Coggan; G Chelvanayagam; S Easteal; L S Jermiin; G K Schulte; D E Danley; L R Hoth; M C Griffor; A V Kamath; M H Rosner; B A Chrunyk; D E Perregaux; C A Gabel; K F Geoghegan; J Pandit
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

6.  Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells.

Authors:  M Styblo; L M Del Razo; L Vega; D R Germolec; E L LeCluyse; G A Hamilton; W Reed; C Wang; W R Cullen; D J Thomas
Journal:  Arch Toxicol       Date:  2000-08       Impact factor: 5.153

7.  A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19.

Authors:  Toru Hayakawa; Yayoi Kobayashi; Xing Cui; Seishiro Hirano
Journal:  Arch Toxicol       Date:  2004-11-04       Impact factor: 5.153

8.  Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMA(V) reductase.

Authors:  R A Zakharyan; H V Aposhian
Journal:  Chem Res Toxicol       Date:  1999-12       Impact factor: 3.739

9.  Biliary and urinary excretion of inorganic arsenic: monomethylarsonous acid as a major biliary metabolite in rats.

Authors:  Z Gregus; A Gyurasics; I Csanaky
Journal:  Toxicol Sci       Date:  2000-07       Impact factor: 4.849

10.  Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine.

Authors:  X C Le; M Ma; W R Cullen; H V Aposhian; X Lu; B Zheng
Journal:  Environ Health Perspect       Date:  2000-11       Impact factor: 9.031

View more
  18 in total

1.  Direct analysis of methylated trivalent arsenicals in mouse liver by hydride generation-cryotrapping-atomic absorption spectrometry.

Authors:  Jenna M Currier; Milan Svoboda; Diogo P de Moraes; Tomás Matousek; Jirí Dĕdina; Miroslav Stýblo
Journal:  Chem Res Toxicol       Date:  2011-03-11       Impact factor: 3.739

2.  Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver.

Authors:  Adam C Straub; Donna B Stolz; Mark A Ross; Araceli Hernández-Zavala; Nicole V Soucy; Linda R Klei; Aaron Barchowsky
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

3.  Arsenic and manganese alter lead deposition in the rat.

Authors:  V Andrade; M L Mateus; D Santos; M Aschner; M C Batoreu; A P Marreilha dos Santos
Journal:  Biol Trace Elem Res       Date:  2014-04-09       Impact factor: 3.738

4.  Arsenic (+ 3 oxidation state) methyltransferase and the methylation of arsenicals in the invertebrate chordate Ciona intestinalis.

Authors:  David J Thomas; Gerardo M Nava; Shi-Ying Cai; James L Boyer; Araceli Hernández-Zavala; H Rex Gaskins
Journal:  Toxicol Sci       Date:  2009-10-15       Impact factor: 4.849

5.  Speciation analysis of arsenic in biological matrices by automated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer).

Authors:  Araceli Hernández-Zavala; Tomáš Matoušek; Zuzana Drobná; David S Paul; Felecia Walton; Blakely M Adair; Dědina Jiří; David J Thomas; Miroslav Stýblo
Journal:  J Anal At Spectrom       Date:  2008       Impact factor: 4.023

6.  Impact of life stage and duration of exposure on arsenic-induced proliferative lesions and neoplasia in C3H mice.

Authors:  Gene J Ahlborn; Gail M Nelson; Rachel D Grindstaff; Michael P Waalkes; Bhalchandra A Diwan; James W Allen; Kirk T Kitchin; R Julian Preston; Araceli Hernandez-Zavala; Blakely Adair; David J Thomas; Don A Delker
Journal:  Toxicology       Date:  2009-05-18       Impact factor: 4.221

7.  Arsenic upregulates MMP-9 and inhibits wound repair in human airway epithelial cells.

Authors:  Colin E Olsen; Andrew E Liguori; Yue Zong; R Clark Lantz; Jefferey L Burgess; Scott Boitano
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-06-06       Impact factor: 5.464

8.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent dimethylated arsenic in mice after oral administration.

Authors:  Michael F Hughes; Vicenta Devesa; Blakely M Adair; Sean D Conklin; John T Creed; Miroslav Styblo; Elaina M Kenyon; David J Thomas
Journal:  Toxicol Appl Pharmacol       Date:  2007-10-22       Impact factor: 4.219

9.  Principles and application of an in vivo swine assay for the determination of arsenic bioavailability in contaminated matrices.

Authors:  Matthew Rees; Lloyd Sansom; Allan Rofe; Albert L Juhasz; Euan Smith; John Weber; Ravi Naidu; Tim Kuchel
Journal:  Environ Geochem Health       Date:  2008-12-23       Impact factor: 4.609

10.  Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites.

Authors:  Hisham A El-Masri; Elaina M Kenyon
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.